I’m not saying AAVL’s phase-1 AMD data were bad, but rather that they weren’t great. I have doubts that AVA-101 will show much benefit when added to SoC in a large, double-masked randomized trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”